There are a number of ongoing legal actions concerning patent rights that could affect the implementation of personalized medicine, such as patents on genes or tests. In an opinion piece at The Scientist, Courtenay Brinckerhoff, a partner at Foley & Lardner, writes that "the question being debated is whether these advances are most likely to flourish within the patent system or outside of it." Do patents, she asks, encourage innovation or prevent competition?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.